A platform trial investigating new combinations of therapies in patients with relapsed multiple myeloma

This trial is open to adults aged 18 and older who have a confirmed diagnosis of multiple myeloma that has come back or stopped responding to past treatments. To take part, you must have already tried between one and three previous treatment courses, and these must have included standard myeloma drugs like proteasome inhibitors (such as bortezomib) and immunomodulatory drugs (such as lenalidomide).

Your doctor will also check that your myeloma can be measured through routine tests. This usually means looking for specific myeloma proteins in your blood or urine, or checking the number of myeloma cells in your bone marrow.

Because we do not yet know how belamaf might affect an unborn baby, you cannot take part if you are pregnant or breastfeeding. Both men and women who could have children must agree to use reliable contraception before, during, and for a set period after the trial ends.

Taking part involves receiving belamaf either by itself or alongside other standard myeloma drugs, depending on which group (or 'arm') of the study you join. You will first enter a safety phase with a small group of patients, where doctors keep a very close watch on how your body handles the medicine. If the dose is safe, more people are invited to join an expansion phase to see how well the treatment fights the cancer.

Belamaf is given in a hospital clinic, usually through a drip into a vein. Because the drug can affect the surface of the eye, you will need regular eye check-ups with an eye specialist alongside your usual cancer appointments. You will also have routine blood tests, urine tests, and health checks to monitor your progress.

You will continue receiving treatment for as long as it helps you and the side effects remain manageable. The study team will follow your health regularly throughout your treatment and for a period afterwards to monitor your long-term recovery.